Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiao Huo Luo Wan is a classic Traditional Chinese Medicine (TCM) formula manufactured by Liaoning Jindan Pharmaceutical. It is primarily indicated for the treatment of Wind-Cold-Dampness Bi-syndrome, which manifests as joint pain, muscle numbness, and limb stiffness, typically associated with conditions such as rheumatoid arthritis and osteoarthritis. The formula consists of six main ingredients: *Arisaema cum Bile* (胆南星), *Aconiti Kusnezoffii Radix Preparata* (制草乌), *Aconiti Radix Cocta* (制川乌), *Olibanum* (乳香), *Myrrha* (没药), and *Lumbricus* (地龙). These components work synergistically to dispel wind, remove dampness, transform phlegm, and unblock the collaterals. Pharmacologically, the preparation exhibits analgesic and anti-inflammatory properties, likely through the modulation of inflammatory cytokines and improvement of local microcirculation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xiao huo luo wan.